EMA Work Plan Targets Priority Drug Review Program

The EMA is planning to focus on 13 separate initiatives for 2017, ranging from fully implementing its priority medicines review pathway to boosting international cooperation.

EMA’s Committee for Medicinal Products for Human Use launched the PRIME program in March 2016 to speed reviews for drugs that fill unmet needs. EMA stakeholders will review the program’s first year next month.

According to the EMA’s 2017 work plan, the committee will also strive for closer collaboration with regulators outside of the European Union. Earlier this year, EMA reached an agreement with the FDA to mutually recognize one another’s drug GMP inspections.